Lexaria Bioscience hires former GW Pharma USA President Julian Gangolli as Strategic Advisor

Lexaria Bioscience Corp.

Julian Gangolli, former President of GW Pharmaceuticals USA, appointed as Strategic Advisor.
He oversaw FDA approval of Epidiolex, the first pure CBD drug, leading to GW's $7.2B acquisition by Jazz.
Previously a senior Allergan executive; part of management that sold Allergan to Actavis in 2015.
Granted 5,000 stock options at $2.73 per share, exercisable for 5 years.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.